| Previous Close | 0.2958 |
| Open | 0.3020 |
| Bid | 0.3400 x 4000 |
| Ask | 0.3640 x 7200 |
| Day's Range | 0.2820 - 0.3800 |
| 52 Week Range | 0.2500 - 6.4000 |
| Volume | 3,267,469 |
| Avg. Volume | 999,006 |
| Market Cap | 3.5M |
| Beta | 0.13 |
| PE Ratio (TTM) | -0.05 |
| EPS (TTM) | -7.15 |
| Earnings Date | Aug 21, 2017 - Aug 25, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- PR Newswire•3 days ago
ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results
-Company to Host Business Update Conference Call and Webcast on August 23, 2017- LOS ANGELES , Aug. 14, 2017 /PRNewswire/ --Â ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) ...
- Accesswire•29 days ago
Today's Research Reports on Stocks to Watch: Capricor Therapeutics and Immunocellular Therapeutics
NEW YORK, NY / ACCESSWIRE / July 19, 2017 / Capricor Therapeutics was a big winner in trading on Tuesday with shares seeing gains of over 100%. The company announced that its drug candidate for the treatment ...
- PR Newswire•last month
ImmunoCellular Therapeutics Announces Pricing of Public Offering of Convertible Preferred Stock and Warrants
LOS ANGELES, July 18, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock ("Preferred Stock") and related warrants ("Warrants") to purchase up to 9,000 shares of Preferred Stock, at a public offering price of $1,000 per share of Preferred Stock and related Warrants, for gross proceeds of approximately $5 million, excluding the proceeds, if any, from the exercise of the Warrants.
